Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...
ADC / XDC
Huadong Medicine’s Elahere Accepted for NMPA Review in China for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC
The European Commission (EC) has granted registration approval for the HER2-directed antibody-drug conjugate (ADC) Enhertu...
MSD Cancels Development of Two Pre-Clinical ADCs from Sichuan Kelun-Biotech
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its innovative drug development subsidiary Sichuan...
Shanghai Fudan-Zhangjiang’s ADC FZ-AD005 Accepted for NMPA Review in Advanced Solid Tumors
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the National...
Hansoh Pharmaceutical and GSK Ink Global Licensing Deal for Innovative ADC HS-20089
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with...
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...
WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...
Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio
US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink...
Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development
German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based...
Mabwell to Present Promising Clinical Data at 2023 ESMO Congress
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the...
Kelun-Biotech to Present SKB264 Study Results for Metastatic Breast Cancer at ESMO
China-based pharmaceutical innovator Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its subsidiary Sichuan Kelun-Biotech...
RemeGen Secures NMPA Approval for Phase II Study of Disitamab Vedotin in Breast Cancer
China-based biopharma RemeGen Ltd (HKG: 9995) has announced that it has received approval from the...
Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates
Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech...
Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4
Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...
ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with...
Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing
Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and...
RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy
China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...
Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...
Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China
The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...